Mental and Behavioral Health

The FDA also recommended a scheduling action for 7-hydroxymitragynine (7-OH), with data showing the drug binds to opioid receptors.

Community pharmacists embrace mental health interventions to combat depression and anxiety in long-term condition patients, enhancing overall care and accessibility.

The risk of untreated depression for pregnant women can cause adverse outcomes, which can include relapse in mood symptoms, suicide, and overdose death.

Older adults with insomnia face heightened depression risks during inflammation, highlighting the need for targeted monitoring and treatment strategies.

Researchers examined the factors attributed to self-reported resilience among diverse and community-dwelling adults during the COVID-19 pandemic.

Pharmacists play a role in educating patients as well as making them feel more comfortable when utilizing opioid use treatment.

Thimerosal is a mercury-containing compound that has been widely used as a preservative in some biological and drug products since the 1930s.

In 2023, drug overdose deaths sustained declines, but there are still disparities that need to be addressed to continue to decrease these numbers.

PET and autopsy assays suggest that Alzheimer disease (AD) and non-AD tau pathologies could be the underlying cause of some late-life mood disorders.

Our whole country needs to do better in providing harm reduction services, including naloxone and syringe service programs.

Investigators found that simvastatin added to escitalopram for patients with obesity and major depressive disorder did not have increased antidepressive effects.

The associations and strengths of these links varied by the complication type, including diabetic nephropathy, neuropathy, and retinopathy.

Researchers aimed to estimate the impact of using behavioral science principles within communication intended for hypertension medication adherence.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

Patients included in the study were aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD).

Researchers conduct a scoping review to update and determine what the best available options are for treating patients with skin-picking disorder.

In children aged 5 to 17 with skin disorders, researchers explore the risk of developing psychosocial comorbidities, sleep disturbances, and common related symptoms.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.

Investigators note that the long-term effects of attention deficit/hyperactivity disorder (ADHD) medication for children remain lacking.

Patients with psychosis, depression, and anxiety exhibit higher rates of vaccine hesitancy.

However, the results show that there was an improvement of symptom scores, although they were not significant.

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

A new study found that GLP-1s were not associated with an increased risk of suicidal ideation, self-harm, or suicide compared to DPP-4 and SGLT-2 inhibitors.